Antibiotic-resistance markers in genetically modified (GM) plants do not pose a substantial risk to human health, concludes a review article published in the October issue of The Lancet Infectious Diseases.
Antibiotic resistance marker genes are used as a tool to recognize the successful introduction into plant cells of a new gene with beneficial characteristics. The markers are coupled with the new gene, so by selecting those cells that express the resistance marker, the cells that have incorporated the gene of interest into their DNA can be identified. Plants derived from these cells neither contain nor produce antibiotics.
The issue of the safety of incorporating antibiotic-resistance markers into GM plants has been a matter of public debate since the early stages of their development. Concern has surrounded the possibility that antibiotic-resistance genes might be passed from GM plants to bacteria, thus creating bacteria that are resistant to antibiotics such as those used to treat common skin, ear, and eye infections.
In this review, authors Stephen Gillespie, of
The authors conclude that whereas there is no evidence that antibiotic resistance from GM crops is being transferred to bacteria, this does not exclude the possibility that it might occur. However, the evidence suggests that, if it occurs at all, the contribution to the burden of antibiotic resistance from GM plants is low, and is dwarfed by inappropriate prescribing of antibiotics in medical practice and their use as animal growth promoters in agriculture.
Gillespie comments, . . . antibiotic-resistance markers do not pose a substantial risk to human health because the contribution that recombinant bacteria might makeshould the enormous barriers to transfer be overcomeis so small that any contribution to antibiotic resistance made by GM plants must be overwhelmed by the contribution made by antibiotic prescription in clinical practice.
Source: The Lancet